|
gptkbp:instanceOf
|
gptkb:drug
gptkb:biologic_medication
|
|
gptkbp:administeredBy
|
ribavirin
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2001
|
|
gptkbp:ATCCode
|
gptkb:L03AB10
|
|
gptkbp:CASNumber
|
198153-51-4
|
|
gptkbp:contraindication
|
autoimmune hepatitis
decompensated liver disease
|
|
gptkbp:developedBy
|
gptkb:Schering-Plough
|
|
gptkbp:drugClass
|
interferons
|
|
gptkbp:eliminationHalfLife
|
40 hours
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:PegIntron
|
|
gptkbp:mechanismOfAction
|
interferon alpha receptor agonist
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:product
|
pegylated interferon alpha-2b
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:depression
gptkb:anemia
fatigue
neutropenia
flu-like symptoms
|
|
gptkbp:UNII
|
39R4TAN1VT
|
|
gptkbp:usedFor
|
gptkb:hepatitis_C
gptkb:hepatitis_B
gptkb:melanoma
|
|
gptkbp:bfsParent
|
gptkb:PEG-Intron
gptkb:PegIntron
gptkb:PEG-INTRON
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
peginterferon alfa-2b
|